The case for & against
Bull & Bear analysis
Bullish
Milestone Pharmaceuticals, Inc. (NASDAQ: MIST) is a developing player in the cardiovascular therapies sector, with a focus on creating innovative treatments for arrhythmias, particularly Paroxysmal Supraventricular Tachycardia (PSVT) and Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR). The company’s lead asset, a nasal spray formulation of atripamil, is designed for rapid, patient-controlled relief of these heart conditions, responding to a significant and growing patient demographic suffering from these conditions.
Bull says
- ↑Phase II Rivera study shows 30 bpm ventricular rate drop vs placebo
- ↑FDA guidance permits single Phase III study, accelerating Q4 2024 approval path
- ↑Insurance covers 50%+ of U.S. lives for CARDAMYST, expanding market reach
- ↑Analyst consensus Moderate Buy, $6.40 target implies ~450% upside from $1.16
- ↑Stock gained 2.6% in three days, MACD positive for short‐term momentum
- ↑Strong cash reserves, high liquidity support trials and commercial launch
Bear says
- ↓Earnings yield at –3.1% and profitability scores negative, highlighting inefficiencies
- ↓Short interest jumped 6%, increasing potential downward pressure
- ↓Analysts are cutting earnings estimates amid negative revision trends
- ↓Regulatory delays could push approval beyond Q4 2024 despite FDA guidance
- ↓Faces robust competition from Pfizer, Merck, Abbott and other AFib treatments
- ↓Reliance on cash runway; any funding gap may delay trials and launch
Investment themes with MIST
Pharmaceuticals↓ -0.08%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Julian Komar's Best Winners (Screen Results)↓ -0.50%
NVDA · GOOGL · AVGO
Earnings Call · Q3 2023 · Mgmt. Guidance
Updated 08-13-2026neutral
Transcript signals
Read full transcript analysis ›